SOMERSET, N.J., May 25, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced it will present at the Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30 am ET. This webcast will […]
. Rolling submission of BLA to the FDA completed for ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) . European Marketing Authorisation Application (MAA) submitted for cilta-cel for the treatment of RRMM . New and updated cilta-cel data to be presented at the upcoming 2021 American Society of Clinical Oncology […]
Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patients with relapsed or refractory multiple myeloma The first presentation of data from the CARTITUDE-2 study of cilta-cel in earlier lines of multiple myeloma treatment SOMERSET, N.J.— (BUSINESS WIRE)—May 12, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in […]
Submission follows accelerated assessment granted by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the application based on positive Phase 1b/2 CARTITUDE-1 study data SOMERSET, N.J., April 30, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of […]
Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million. U.S. FDA clearance for IND application for a Phase 1 clinical trial to evaluate LB1901 in relapsed or refractory T-cell lymphoma (RR TCL). Rolling submission of BLA to the […]
SOMERSET, N.J., March 10, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will release its fourth quarter and full-year 2020 financial results before U.S. financial markets open on Thursday, March 18, 2021. Legend Biotech […]
SOMERSET, N.J.—(BUSINESS WIRE)— February 19, 2021— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today in conjunction with an announcement to be issued by Legend Biotech’s majority parent company GenScript Biotech Corporation, pursuant to the rules […]
SOMERSET, N.J., February 1, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted a request […]
SOMERSET, N.J., December 15, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. Ying Huang, PhD, Chief Executive Officer […]
Legend Biotech also achieves fifth milestone payment under its collaboration agreement with Janssen in clinica development of cilta-cel SOMERSET, N.J., December 21, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today the initiation […]
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.